A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy - Summary - MDSpire
Advertisement
A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy
To create a framework for assessing the feasibility of generating pivotal data to support FDA regulatory approval of vaccines and therapeutics specifically against emerging viral pathogens.
Key Findings:
Vaccine development is currently more feasible than therapeutics for the assessed pathogens, highlighting the need for targeted investment.
Eight central factors were identified that impact the feasibility of MCM development and FDA approval, which should be prioritized in future efforts.
Close consultation with the FDA is essential for defining regulatory strategies and ensuring successful product development.
Interpretation:
The framework supports efficient resource allocation by identifying MCM candidates with high potential for FDA approval, thereby enhancing national preparedness against emerging pathogens through informed decision-making.
Limitations:
Focuses solely on FDA approval requirements, excluding other regulatory authorities, which may limit applicability in a global context.
Does not address diagnostic and device development, which are also crucial for comprehensive MCM development and response strategies.
Conclusion:
The framework provides a structured approach to advance MCM development, promoting timely availability during public health emergencies and strengthening national health security.
by Richard C White, Rachael G Lewis, James D Little, Brenda L Fredericksen, Carol L Sabourin, M Chelsea Lane, Shannon G Loelius, Kimberly A Hofmeyer, Matthew Steele, Xiaomi Tong, Robert A Johnson
Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.
